Executive summary
US Patent 5,096,890 is a chemistry-first patent that claims a defined set of substituted pyrrolidine derivatives as muscarinic receptor antagonists, plus composition and method-of-treatment claims (notably irritable bowel syndrome). The claim set is broad at the formula level but narrows through variable definitions (Y linkers, R1 heteroaryl core and ring-atom constraints), and it crystallizes commercial-relevant embodiments into specific stereoisomers and a named compound. The patent’s enforceable scope in the US is primarily driven by whether an accused compound falls within the literal formula parameters (or equivalence) and whether a challenger can design around variable elements (Y linker, R1 heterocycle, and the carbamoyl/benzofuran-pyrrolidine framework).
US Patent 5,096,890 landscape: scope, claims, and patent estate for muscarinic receptor antagonists
What does the scope of US 5,096,890 cover at the formula level?
Core claim target: compounds of a generalized chemical formula “of the formula” with constrained substituent definitions, where the compounds antagonize muscarinic receptors.
Claim 1 is the pivotal scope anchor because it defines:
- A chemical scaffold connected via Y (allowed linkers).
- A substituent R = –CONH2 (carbamoyl).
- A substituent R1 defined by an additional heteroaryl-linked fragment with constraints on ring atoms and heterocycles.
Claim 1 key limiting variables
Y (link to the pyrrolidine framework):
- direct link, or
- –CH2–, or
- –(CH2)2–, or
- –CH2O–, or
- –CH2S–
R is fixed:
R1 structure constraints:
- R1 is a group of another formula where:
- X and X1 are each independently O or CH2
- m is 1, 2, or 3
- Het is pyridyl, pyrazinyl or thienyl
Practical implication for freedom-to-operate:
An accused muscarinic antagonist will more likely avoid infringement if it uses a different terminal group than carbamoyl (–CONH2), uses a linker not in the enumerated set for Y, or uses a heteroaryl substituent for Het that is not pyridyl, pyrazinyl, or thienyl, or uses ring-atom patterns not matching the X/X1 selection and m positioning.
How broad is claim 1 compared with the dependent claims?
Broadest coverage = claim 1 formula.
Dependent claims reduce scope by:
- tightening R1 sub-structure (claims 2 and 3),
- tightening Y (claims 4 and 5),
- restricting stereochemistry (claim 6),
- specifying a named stereochemically defined embodiment (claim 7),
- adding composition and method-of-use layers (claims 8–10).
Claim 2 and Claim 3 narrow R1
- Claim 2: restricts R1 to a further defined subgroup using the same variables (X, X1, Het, m).
- Claim 3: restricts R1 again to a narrower defined structure.
Practical implication: the broadest literal claim coverage is at claim 1; if a challenger avoids claim 1’s exact R1 variant, they may still fall into claim 2 or 3 if those sub-variants are present.
Claim 4 and Claim 5 narrow Y
- Claim 4: limits Y to “direct link or –CH2–”
- Claim 5: further limits Y to “–CH2–”
This is material for design-around: many analogs keep the core but adjust linker length or heteroatom in the tether; claim 1 covers multiple linkers, but claims 4–5 are narrower.
What stereochemistry is protected?
Claim 6 covers stereoisomeric scope:
- “3R,S-(racemic) or 3S-form.”
Claim 7 names two specific stereochemical species:
- 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidine
- 3-(S)-(-)-(1-carbamoyl-1,1-diphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidine
Practical implication: If an accused drug is marketed or developed as a specific enantiomer or racemate, claim 6 and claim 7 increase infringement risk. Even if the chemical class is altered, stereochemical alignment with the protected “3S” or racemic forms matters for literal coverage.
Which specific chemical features are required for literal infringement?
Claim 1’s literal infringement requires simultaneous match of the constrained features:
- Carbamoyl group (R = –CONH2).
- Linker Y is one of the five enumerated variants.
- The R1 portion must satisfy:
- X and X1 are O or CH2
- Het is limited to pyridyl, pyrazinyl, or thienyl
- m ∈ {1,2,3}
- The overall compound matches the formula’s scaffold arrangement (pyrrolidine framework with the benzofuran/ethyl and diphenylmethyl carbamoyl motif as implied by claim 7’s named structure).
Design-around levers (most credible):
- replace –CONH2 with an alternative carbonyl substituent (e.g., ester, amide with different N-substitution, urea, sulfonamide)
- choose a Het heteroaryl outside pyridyl/pyrazinyl/thienyl
- change X/X1 selection from O/CH2 in the required positions
- use a Y linker outside the claimed list
Does US 5,096,890 claim pharmaceutical compositions or only molecules?
Yes. Claim 8 adds a pharmaceutical composition claim:
- “a pharmaceutical composition comprising a muscarinic receptor antagonizing effective amount” of a compound of claim 1
- plus “pharmaceutically acceptable diluent or carrier”
Scope consequences:
- Composition claims can be asserted even when the active ingredient matches claim 1.
- The “diluent or carrier” language is generic, so the key question is whether the active ingredient (API) infringes.
What medical uses are covered, and how strong are the method-of-use claims?
Claim 9 and Claim 10 define method-of-treatment use:
- Claim 9: administering a “muscarinic receptor antagonizing amount” for a disease associated with altered smooth muscle motility or tone.
- Claim 10: the disease is irritable bowel syndrome.
Enforceability posture (US litigation pattern):
- If a defendant sells an infringing compound, method claims can become relevant in enforcement where there is evidence of label-consistent use, marketing, or induced administration tied to IBS.
Scope limit note:
The claims are framed around “administering … to a mammal” and the disease context. If an accused product targets a different indication or is used for a different therapeutic purpose, the method claim’s practical reach changes even when chemistry overlaps.
What named embodiment is explicitly covered?
Claim 7 is a strong anchor because it ties the broader genus to specific stereoisomeric species and includes a fully specified structural description. That named compound is the most litigation-ready “pull-through” point because it converts formula ambiguity into a concrete target.
If an accused product API matches the named compound (racemic or 3S), the infringement analysis can focus on stereochemical and identity confirmation.
How should an investor or licensing team assess the patent strength of US 5,096,890?
What is the expected expiration timeline in the US?
US chemical patents typically expire based on earliest nonprovisional filing date plus 20 years, subject to adjustments/extensions. This is critical for settlement leverage and licensing value.
However, this prompt provides no filing date, priority date, patent grant date, or PTA/term extension details. Without those, a complete and accurate exclusivity/expiration timeline cannot be produced.
What factors make claim 1 harder or easier to design around?
Hard to design around because:
- Y includes multiple linker options, capturing common linker variants.
- R is fixed to carbamoyl.
- Het includes three heteroaryls that are also common in medicinal chemistry.
Easier to design around because:
- R1 is constrained by X/X1 being O or CH2 and by m being only 1 to 3.
- Het is limited to pyridyl/pyrazinyl/thienyl, excluding other heteroaryls that might otherwise be used.
How many separate “infringement routes” exist in this patent?
- Literal infringement of claim 1 via genus coverage.
- Literal infringement of claim 2/3 via narrower R1 variants.
- Literal infringement of claim 4/5 via narrower Y.
- Literal infringement of claim 6 via stereochemical restriction.
- Literal infringement of claim 7 via the specific named stereoisomers.
- Composition infringement (claim 8) if API infringes.
- Method infringement (claims 9–10) if administration/use aligns to muscarinic antagonism and IBS.
This layered claim structure increases leverage when an accused drug is close to the named compounds.
What would a competitive landscape mapping look like for this patent scope?
This patent defines a genus for muscarinic antagonists with a carbamoylated diphenylmethyl group and benzofuran-ethyl-pyrrolidine motif plus heteroaryl substitution.
But this prompt provides no references to:
- the drug name(s) corresponding to the genus,
- the Orange Book status,
- specific generic applicants,
- Paragraph IV filings,
- litigation dockets,
- family members (continuations/divisionals),
- or international filings.
Without that, a credible, data-backed landscape cannot be constructed.
Key Takeaways
- US 5,096,890 claim 1 protects a genus of muscarinic receptor antagonists defined by: enumerated Y linkers, fixed carbamoyl (–CONH2), and constrained R1 heteroaryl chemistry where Het is pyridyl, pyrazinyl, or thienyl and where X/X1 are O or CH2 with m = 1–3.
- Dependent claims materially narrow the protected space by tightening R1, restricting Y to direct link or –CH2– (and specifically –CH2–), and limiting stereochemistry to 3R,S/racemic and/or 3S forms.
- Claim 7 identifies explicit stereochemical species, giving the patent a concrete enforcement target beyond abstract formula coverage.
- Claim 8 adds composition coverage (API + diluent/carrier).
- Claims 9–10 add therapeutic use protection for smooth muscle motility/tone disorders and expressly irritable bowel syndrome (IBS).
- For design-around, the highest-impact levers are replacing –CONH2, altering Y beyond the enumerated set, and using Het outside pyridyl/pyrazinyl/thienyl or changing the allowed X/X1 and m constraints.
FAQs
1) Which part of US 5,096,890 most directly determines whether an accused API infringes?
Claim 1’s formula limitations: Y, fixed R = –CONH2, and constrained R1 including Het, X/X1, and m.
2) Does US 5,096,890 cover stereoisomer-specific products?
Yes. Claim 6 limits to 3R,S (racemic) and/or 3S, and claim 7 specifies explicit 3-(R,S) and 3-(S) named embodiments.
3) Are composition and method-of-use claims available if chemistry matches claim 1?
Yes. Claim 8 covers compositions with the claim 1 compound plus carrier, and claims 9–10 cover administration for smooth muscle tone/motility disorders including IBS.
4) What are the most plausible chemical design-around strategies?
Change or remove the fixed carbamoyl (–CONH2), select a Y linker not within claim 1’s enumerated options, and use R1/Het structures outside the claimed Het set and allowed X/X1/m constraints.
5) Is the strongest enforcement hook claim 1 or claim 7?
Claim 1 is the broadest genus entry point; claim 7 is typically the strongest for identity-focused enforcement because it ties protection to specific stereochemical species.
References (APA)
- United States Patent 5,096,890.
